非侵入性眼后段给药的纳米药物递送策略研究进展

Abstract
Figure/Table
References (31)
Related Citation (1)

Download: PDF (572 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Because of the unique physiological structure of eyes, routine eye topical administration for the treatment of posterior eye disease has always been a difficult problem for medical workers. The developed drug delivery system of eyes based on nano-drug delivery strategy has characters of small size, strong penetration, strong surface adhesion for biofilm, and so on, which is expected to develop into a safe, effective, economical and non-invasive new eye drug delivery system, in particular, more and more attention has been paid to drug administration in the posterior eye segment. This paper focuses on the various nano-drug delivery strategies of non-invasive drug administration of the posterior eye segment, including drug delivery systems of nanoparticles, lipidosome, nano-micelle, nano suspensions and nanoemulsion.

Key words： Non-invasive Posterior eye segment Nanotechnology Drug delivery system

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	DAI Zhu1
	2 ZHU Hongda1

Cite this article:

DAI Zhu1,2 ZHU Hongda1. Reseach progress on nano-drug delivery strategy of non-invasive drug administration of the posterior eye segment[J]. 中国医药导报, 2019, 16(16): 46-49.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2019/V16/I16/46

[1] Thevi T，Maizura Z，Abas AL. The Melaka Hospital cataract complications study analysis of 12，992 eyes [J]. Indian J Ophthalmol，2017，65（1）：24-29.
[2] Bourne R，Flaxman SR，Braithwaite T，et al. Magnitude，temporal trends，and projections of the global prevalence of blindness and distance and near vision impairment：a systematic review and meta-analysis [J]. Lancet Glob Health， 2017，5（1）：e888-e897.
[3] Janagam DR，Wu L，Lowe TL. Nanoparticles for drug delivery to the anterior segment of the eye [J]. Adv Drug Deliv Rev，2017，122（1）：31-64.
[4] Thrimawithana TR，Young S，Bunt CR，et al. Drug delivery to the posterior segment of the eye [J]. Drug Discov Today，2011，16（5/6）：270-277.
[5] Agarwal R，Iezhitsa I，Agarwal P，et al. Liposomes in topical ophthalmic drug delivery：an update [J]. Drug Deliv，2016，23（4）：1075-1091.
[6] Cholkar K，Patel A，Vadlapudi AD，et al. Novel Nanomicellar Formulation Approache for Anterior and Posterior Segment Ocular Drug Delivery [J]. Recent Pat Nanomed，2012，2（2）：82-95.
[7] Balguri SP，Adelli GR，Majumdar S. Topical ophthalmic lipid nanoparticle formulations（SLN，NLC）of indomethacin for delivery to the posterior segment ocular tissues [J]. Eur J Pharm Biopharm，2016，109：224-235.
[8] Vandamme TF. Microemulsions as ocular drug delivery systems：recent developments and future challenges [J]. Prog Retin Eye Res，2002，21（1）：15-34.
[9] Abdullah TA，Ibrahim NJ，Warsi MH. Chondroitin sulfate-chitosan nanoparticles for ocular delivery of bromfenac sodium：Improved permeation，retention，and penetration [J]. Int J Pharm Investig，2016，6（2）：96-105.
[10] Fialho SL，Behar-Cohen F，Silva-Cunha A. Dexamethasone-loaded poly（e-caprolactone）intravitreal implants：A pilot study [J]. Eur J Pharm Biopharm，2008，68（3）：637-646.
[11] Kadam RS，Tyagi P，Edelhauser HF，et al. Influence of choroidal neovascularization and biodegradable polymeric particle size on transscleral sustained delivery of triamcinolone acetonide [J]. Int J Pharm，2012，434（1/2）：140-147.
[12] Vasconcelos A，Vega E，Perez Y，et al. Conjugation of cell penetrating peptides with poly（lactic-co-glycolicacid）-polyethylene glycol nanoparticales improves ocular drug delivery [J]. Int J Nanomedicine，2015，10（2）：609-631.
[13] Tahara K，Karasawa K，Onodera R，et al. Feasibility of drug delivery to the eye′s posterior segment by topical instillation of PLGA nanoparticles [J]. Asian J Pharm Sci，2017，12（4）：394-399.
[14] Wang X，Yu B，Ren W，et al. Topical ophthalmic lipid nanoparticle formulations（SLN，NLC）of indomethacin for delivery to the posterior segment ocular tissues [J]. Eur J Pharm Biopharm，2013，172（3）：690-698.
[15] Sánchez-López E，Espina M，Doktorovova S，et al. Lipid nanoparticles（SLN，NLC）：Overcoming the anatomical and physiological barriers of the eye（Part Ⅱ）Ocular drug-loaded lipid nanoparticles [J]. Eur J Pharm Biopharm，2017，110：58-69.
[16] 李沙沙，孙朋超，黄维维，等.眼部给药系统研究新进展[J].中国医药工业杂志，2015，46（1）：97-104.
[17] 蒋敏，甘莉，甘勇，等.新型眼用脂质载体制剂的研究进展[J].中国药学杂志，2012，47（16）：1265-1270.
[18] Li N，Zhuang CY，Wang M，et al. Low molecular weight chitosan-coated liposomes for ocular drug delivery：In vitro and in vivo studies [J]. Drug Deliv，2012，19（1）：28-35.
[19] Zhang J，Liang X，Li X，et al. Ocular delivery of cyanidin-3-glycoside in liposomes and its prevention of selenite-induced oxidative stress [J]. Drug Dev Ind Pharm，2016，42（4）：546-553.
[20] Fujisawa T，Miyai H，Hironaka K，et al. Liposomal diclofenac eye drop formulations targeting the retina：Formulation stability improvement using surface modification of liposomes [J]. Int J Pharm，2012，436（1）：564-567.
[21] Davis BM，Normando EM，Guo L，et al. Topical delivery of Avastin to the posterior segment of the eye in vivo using annexin A5-associated liposomes [J]. Small，2014，10（8）：1575-1584.
[22] Mandal A，Bisht R，Rupenthal ID，et al. Polymeric micelles for ocular drug delivery：From structural frameworks to recent preclinical studies [J]. J Control Release，2017，248（1）：96-116.
[23] Toshida H，Funaki T，Ono K，et al. Efficacy and safety of retinol palmitate ophthalmic solution in the treatment of dry eye：a Japanese Phase Ⅱ clinical trial [J]. Drug Des Develo Ther，2017，11（1）：1871-1879.
[24] Patel A，Cholkar K，Agrahari V，et al. Ocular drug delivery systems：An overview [J]. World J Pharmacol，2013，2（2）：47-64.
[25] Ideta R，Tasaka F，Jang WD，et al. Nanotechnology based photodynamic therapy for neovascular disease using a supramolecular nanocarrier loaded with a dendritic photos ensitizer [J]. Nano Lett，2005，5（12）：2426-2431.
[26] Ako-Adounvo AM，Nagarwal RC，Oliveira L，et al. Recent Patents on Ophthalmic Nano-formulations and Therapeutic Implications [J]. Recent Pat Drug Deliv Formul，2014，8（3）：193-201.
[27] Pignatello R，Ricupero N，Bucolo C，et al. Preparation and characterization of eudragit retard nanosuspensions for the ocular delivery of cloricromene [J]. AAPS Pharm Sci Tech，2006，7（1）：E192-E198.
[28] Baspinar Y，Bertelmann E，Pleyer U，et al. Corneal permeation studies of everolimus microemulsion [J]. J Ocul Pharmacol Ther，2008，24（4）：399-402.
[29] 邓广汉，班俊峰，张彦，等.香豆素-6纳米探针的制备及其眼部给药适应性评价[J].中国医药工业杂志，2016， 47（3）：305-310.
[30] 邵智慧，王健.眼后段给药系统与给药技术[J].世界临床药物，2013，34（7）：431-436.
[31] Esther E，Faik O，Yanir A，et al. Charged nanoparticles delivery to the eye using hydrogel iontophoresis [J]. J Control Release，2008，126（2）：156-161.